| diabetes type 2 | All results are NS for efficacy | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| Seino, 2009 | vs placebo | | | nausea ∞ [NaN; ∞] vomiting ∞ [NaN; ∞] diarrhoea ∞ [NaN; ∞] treatment-emergent
adverse events (TEAEs) 2.25 [0.33; 15.27] | | Rosenstock (30 mg weekly), 2009 | vs placebo | HbA1c inf a 7% 2.59 [1.34; 4.99] | | CV events NaN [NaN; NaN] | | Rosenstock (30 mg every two weeks), 2009 | vs placebo | HbA1c inf a 7% 2.50 [1.30; 4.81] | | CV events ∞ [NaN; ∞] |
| Trial | Treatments | Patients | Method |
|---|
| Seino, 2009 | albiglutide 15 mg weekly, 30 mg weekly, 50 mg biweekly, and
100 mg monthly (n=32) vs. placebo (n=8) | Japanese subjects
with type 2 diabetes mellitus | single-blind Parallel groups Sample size: 32/8 Primary endpoint: not unique FU duration: 4 weeks (+5 wk) phase 2 | | Rosenstock (30 mg weekly), 2009 | albiglutide
30mg weekly (n=31) vs. placebo (n=52) 8 arms with liraglutide and 1 arm with exenatide twice daily (+1 arm receiving placebo): albiglutide
weekly (4, 15, or 30 mg), every 2 weeks
(biweekly; 15, 30, or 50 mg), or monthly
(50 or 100 mg) | patients with type 2 diabetes inadequately controlled with diet and exercise or
metformin monotherapy | double-blind Parallel groups Sample size: 31/52 Primary endpoint: FU duration: 16 weeks phase 2 | | Rosenstock (30 mg every two weeks), 2009 | albiglutide
30mg weekly
(n=32) vs. placebo
(n=50) 8 arms with liraglutide and 1 arm with exenatide twice daily (+1 arm receiving placebo): albiglutide
weekly (4, 15, or 30 mg), every 2 weeks
(biweekly; 15, 30, or 50 mg), or monthly
(50 or 100 mg)
| patients with type 2 diabetes inadequately controlled with diet and exercise or
metformin monotherapy
| double blind Parallel groups Sample size: 32/50 Primary endpoint: 0 FU duration: 16 weeks phase 2
|
|
